What is the 13F Pro Quality Score for ZBH?

13F Pro ranks ZIMMER BIOMET HOLDINGS, INC. (ZBH) on the 13F Pro Quality Score, a 0–100 composite of 32 fundamental signals including return on invested capital, free cash flow consistency, balance-sheet strength, earnings quality, growth durability, and valuation discipline. The score refreshes after each 10-K and 10-Q filing on SEC EDGAR. View ZBH's current score at https://13fpro.ai/research/ZBH (free sign-up required for the full ranking).

Which hedge funds own the most ZBH stock?

Based on the most recent Form 13F-HR filings on SEC EDGAR, the largest reported institutional holders of ZBH include DODGE & COX, BlackRock,, HARRIS ASSOCIATES L P. Holdings are reported quarterly within 45 days of quarter-end and updated on https://13fpro.ai/research/ZBH as soon as new 13F filings post.

Where does 13F Pro source ZBH data?

All ZIMMER BIOMET HOLDINGS, INC. fundamentals and ownership data come directly from SEC EDGAR. ZIMMER BIOMET HOLDINGS, INC. files with the SEC under CIK 1136869. 13F Pro ingests XBRL financial facts from 10-K and 10-Q filings, Form 13F-HR institutional holdings, and Form 4 insider transactions, with no third-party rewrites or estimates.

What sector is ZBH in?

ZIMMER BIOMET HOLDINGS, INC. (ZBH) is classified in the Healthcare sector. 13F Pro publishes sector-level fund flow analysis and quality leaders at https://13fpro.ai/research/sector/healthcare.

How often is ZBH research updated on 13F Pro?

ZBH's fundamentals refresh within hours of each new 10-K or 10-Q filing on SEC EDGAR. Institutional ownership updates after each quarterly 13F filing window. Insider transactions update after each Form 4 filing. The 13F Pro Quality Score recalculates after every fundamentals refresh.

ZIMMER BIOMET HOLDINGS, INC.(ZBH)Stock Analysis

AI analysis on 2,800+ stocks →Deep AI analysis on 2,800+ stocks →

Healthcare →NYSE

Institutional-grade research for retail investors

SEC EDGAR: CIK 1136869 ZBH stock profile & AI dashboard →

13F Pro Quality Score

64.9/100

Rank #606 of 2,879 stocksTOP 25%

View Healthcare peers →

Rankings refresh quarterly once 80% of peers have filed (~45 days after quarter-end). Next update: ~Aug 14, 2026.

Revenue Growth

50.4/100

Profitability

64.5/100

Balance Sheet

60.8/100

Earnings Quality

41.2/100

Free Cash Flow

74.9/100

Institutional Flow

81.4/100

Revenue Scale

84.4/100

Dilution Risk

54.8/100

ZBH Stock Analysis & AI Quality Score

AI stock analysis and institutional research for ZIMMER BIOMET HOLDINGS, INC. (ZBH), a Healthcare sector company. 13F Pro's AI-powered ranking engine scores ZBH at 64.9/100 on a 32-signal composite quality model, placing it at rank #606 of 2,879 stocks — the top 25% of the AI-ranked universe. ZBH scores in the top quartile across revenue scale (84.4), institutional flow (81.4). Based on the latest XBRL financial filings (Q1 2026), ZIMMER BIOMET HOLDINGS, INC. reports quarterly revenue of $2.1B, net income of $238.1M, an operating margin of 17.9%. Top institutional holders of ZBH by reported 13-F value include DODGE & COX, BlackRock,, HARRIS ASSOCIATES L P, based on the most recent SEC filings. ZBH trades on the NYSE exchange and files with the SEC under CIK 1136869. 13F Pro's AI research platform runs 10 specialized AI analysts — value, growth, momentum, macro, and activist specialists — that debate ZBH daily and publish AI-generated analysis with cited SEC sources. The platform aggregates historical XBRL financial facts, 10-Q and 10-K filings, insider Form 4 transactions, and institutional 13-F holdings for ZIMMER BIOMET HOLDINGS, INC. directly from SEC EDGAR. ZIMMER BIOMET HOLDINGS, INC.'s 13F Pro composite quality score has ranged between 8 and 67 since 2021, currently 64.9 — an improving long-term trajectory across 56 quarterly and live scoring snapshots.

✦

Fun facts about ZIMMER BIOMET HOLDINGS, INC.

Quirks, history, and lore behind ZBH — the kind of stuff that makes a stock memorable.

1
The Basics
U.S. medical device company · large-cap · listed on the NYSE · headquartered in a small Indiana city that calls itself the orthopedic capital of the world.
2
The Numbers
Annual revenue roughly $7–8 billion, with operations in over 25 countries and tens of thousands of employees — all in service of one very specific part of the human body.
3
The History
Its current form was born from a 2015 merger of two orthopedic giants — one founded in the 1920s in Indiana, the other a spinoff from a major medical conglomerate — creating a single dominant force in reconstructive joints.
4
The Secret
The company holds a commanding share of the global market for knee and hip replacement implants, meaning its handiwork is quietly installed in millions of aging knees worldwide.
5
The Lore
Warsaw, Indiana — population under 15,000 — is home to this company and several rivals, making it arguably the Silicon Valley of fake hips. The town basically runs on titanium and polyethylene.
6
The Giveaway
Two orthopedic titans — one named for a zimmer frame (well, sort of) and one named Biomet — merged their hip-and-knee empires and now hold a ZBH ticker on the NYSE.

▶ Think you know your stocks? Play the Daily Ticker

Revenue

Q1 2026

$2.1B

Net Income

Q1 2026

$238.1M

Free Cash Flow

Q1 2026

$323.1M

Operating Margin

Q1 2026

17.9%

ROIC

Q1 2026

2.0%

D/E Ratio

Q1 2026

0.59

Revenue & Net Income

Earnings Per Share

Key Financials Over Time

Export Financial Table · Pro+

Revenue

+7.2% YoY

$8.23BFY 2025

FY21 $6.83BFY23 $7.39BFY24 $7.68BFY25 $8.23B

Net Income

-22.0% YoY

$705.1MFY 2025

FY21 $401.6MFY23 $1.02BFY24 $903.8MFY25 $705.1M

Operating Income

-14.6% YoY

$1.10BFY 2025

FY21 $860.3MFY23 $1.28BFY24 $1.29BFY25 $1.10B

EPS (Diluted)

-19.9% YoY

$3.55FY 2025

FY21 $1.91FY23 $4.88FY24 $4.43FY25 $3.55

Total Assets

+8.1% YoY

$23.09BFY 2025

FY21 $23.46BFY23 $21.50BFY24 $21.37BFY25 $23.09B

Total Debt

+21.2% YoY

$7.52BFY 2025

FY21 $7.10BFY23 $5.80BFY24 $6.20BFY25 $7.52B

Op. Cash Flow

+13.2% YoY

$1.70BFY 2025

FY21 $1.50BFY23 $1.58BFY24 $1.50BFY25 $1.70B

Metric	FY 2025	FY 2024	FY 2023	FY 2021	FY 2020	FY 2018
Revenue	$8.23B +7.2%	$7.68B +3.8%	$7.39B +8.3%	$6.83B +11.4%	$6.13B -22.8%	$7.93B
Net Income	$705.1M -22.0%	$903.8M -11.7%	$1.02B +155.0%	$401.6M +389.1%	$-138.9M +63.4%	$-379.2M
Operating Income	$1.10B -14.6%	$1.29B +0.6%	$1.28B +48.5%	$860.3M +935.3%	$83.1M +145.9%	$33.8M
EPS (Diluted)	$3.55 -19.9%	$4.43 -9.2%	$4.88 +155.5%	$1.91 +385.1%	$-0.67 +64.0%	$-1.86
Total Assets	$23.09B +8.1%	$21.37B -0.6%	$21.50B -8.4%	$23.46B -3.9%	$24.42B +1.2%	$24.13B
Total Debt	$7.52B +21.2%	$6.20B +7.0%	$5.80B -18.3%	$7.10B -12.3%	$8.10B -9.4%	$8.94B
Operating Cash Flow	$1.70B +13.2%	$1.50B -5.2%	$1.58B +5.5%	$1.50B +24.5%	$1.20B -31.1%	$1.75B

AI Insight: ZBH Financial Trends

Revenue growth accelerated to 9% year-over-year in Q1 2026, but total debt surged 29% over two years while net income remains volatile.

• Revenue grew from $1,909M in Q1 2025 to $2,087M in Q1 2026, marking 9% year-over-year growth.

• Operating cash flow improved from $359M in Q1 2026 versus $383M in Q1 2025, showing modest decline.

• Operating income rebounded to $373M in Q1 2026 from $154M in Q4 2025, recovering from prior quarter weakness.

⚠ Total debt climbed from $5,835M in Q2 2024 to $7,471M in Q1 2026, a 28% increase over eight quarters.

⚠ Net income volatility persists with swings from $139M to $238M across recent quarters despite revenue growth.

AI Insight: ZBH Ratio Trends

Zimmer Biomet's profitability shows volatile swings with Q4 2025 operating margin collapsing to 6.9% before rebounding to 17.9% in Q1 2026.

• Operating margin plummeted from 17.5% in Q3 2025 to 6.9% in Q4 2025, then recovered to 17.9% in Q1 2026.

• ROIC declined from 8.3% in Q4 2024 to 3.1% in Q4 2025 before improving to 7.4% in Q1 2026.

• Debt-to-equity ratio increased from 0.46 in Q2 2024 to 0.64 in Q3 2025, stabilizing at 0.59 recently.

⚠ Q4 2025 saw dramatic margin compression across all metrics — potential one-time charges or operational disruption.

⚠ TTM operating margin of 14.0% trails Q1 2026's 17.9%, suggesting recent quarter improvement may not sustain annually.

Get alerted when ZBH's score changes

Free account: watchlist tracking, the daily AI brief, and the AI screener.

Passwordless sign-in · Payments by Stripe · Auth by Clerk

Available Research

13F Pro tracks comprehensive data for ZIMMER BIOMET HOLDINGS, INC. including:

SEC EDGAR filings (10-K, 10-Q, 8-K)

XBRL financial facts (revenue, EPS, margins)

Insider transactions (Form 4)

Institutional 13F holdings

Quality rankings (32 signals)

AI analyst debates & daily meetings

Historical financial trends

Peer comparison & sector analysis

Top Institutional Holders of ZBH

DODGE & COX
$2.1B23,542,700 sh
BlackRock, Inc.
$1.4B15,340,806 sh
HARRIS ASSOCIATES L P
$1.2B12,959,939 sh
VANGUARD CAPITAL MANAGEMENT LLC
$1.2B12,793,412 sh
Capital International Investors
$824.6M9,119,222 sh
STATE STREET CORP
$800.1M8,825,127 sh
VANGUARD PORTFOLIO MANAGEMENT LLC
$782.2M8,650,228 sh
FRANKLIN RESOURCES INC
$493.0M5,452,665 sh
GEODE CAPITAL MANAGEMENT, LLC
$484.6M5,379,525 sh
AMERICAN CENTURY COMPANIES INC
$358.4M3,963,206 sh

Fund	Value	Shares
DODGE & COX	$2.1B	23,542,700
BlackRock, Inc.	$1.4B	15,340,806
HARRIS ASSOCIATES L P	$1.2B	12,959,939
VANGUARD CAPITAL MANAGEMENT LLC	$1.2B	12,793,412
Capital International Investors	$824.6M	9,119,222
STATE STREET CORP	$800.1M	8,825,127
VANGUARD PORTFOLIO MANAGEMENT LLC	$782.2M	8,650,228
FRANKLIN RESOURCES INC	$493.0M	5,452,665
GEODE CAPITAL MANAGEMENT, LLC	$484.6M	5,379,525
AMERICAN CENTURY COMPANIES INC	$358.4M	3,963,206

More Healthcare Companies

View all Healthcare →

AAPG

ASCENTAGE PHARMA GROUP INTERNATIONAL

AARD

Aardvark Therapeutics, Inc.

ABBV

AbbVie Inc.

ABCL

AbCellera Biologics Inc.

ABEO

ABEONA THERAPEUTICS INC.

ABOS

Acumen Pharmaceuticals, Inc.

ABPWW

Abpro Holdings, Inc.

ABSI

Absci Corp

Put ZBH on your watchlist

Track score changes the day ZIMMER BIOMET HOLDINGS, INC. files with the SEC, follow the hedge funds that own it, screen 2,800+ AI-scored stocks, and get the daily brief — free.

View Pricing

Free tier includes 13F data, economic indicators, and market overview. Pro starts at $6.67/mo (billed annually).

Passwordless sign-in · Payments by Stripe · Auth by Clerk

Popular Research

AAPL

Apple

MSFT

Microsoft

NVDA

NVIDIA

GOOG

Alphabet

AMZN

Amazon

Is ZBH a good stock to buy?

13F Pro's AI-powered analysis of ZIMMER BIOMET HOLDINGS, INC. (ZBH) draws on SEC EDGAR-sourced fundamentals, institutional 13F holdings, and insider Form 4 transactions in the Healthcare sector (listed on NYSE). The 32-signal AI Quality Score, current rank, and full bull/bear verdict for ZBH are available on the ZBH stock profile dashboard — with the same data, AI insights, ratios, and institutional activity refreshed after every 10-K, 10-Q, 13F, and Form 4 filing.

Which hedge funds own ZBH?

Institutional investors are required to disclose their holdings quarterly via SEC Form 13F. 13F Pro aggregates these filings to show which hedge funds, mutual funds, and asset managers are buying or selling ZBH. Combined with insider transaction data from Form 4 filings and AI-powered analysis from 10 specialized research agents, 13F Pro provides a comprehensive view of ZIMMER BIOMET HOLDINGS, INC.'s investment landscape.